Summary & Overview
Coronary Bypass with Cardiac Catheterization or Open Ablation without MCC: Inpatient Reimbursement Overview
DRG 234 includes coronary artery bypass grafting combined with cardiac catheterization or open ablation procedures without Major Complication or Comorbidity, defining the clinical scope for reimbursement. Correct assignment affects Medicare inpatient payment through grouping and relative resource use.
DRG 234 Overview
DRG 234 covers inpatient admissions for coronary artery bypass grafting performed with concurrent diagnostic cardiac catheterization or open ablation procedures when no Major Complication or Comorbidity is present. This Diagnosis-Related Group captures complex cardiovascular surgical care involving revascularization and adjunct intracardiac procedures. It matters for Medicare payment because case grouping influences base reimbursement and resource weighting for hospitals. Accurate clinical coding of procedures and comorbid conditions determines proper allocation to this Diagnosis-Related Group and associated payment.
National Payment Rates
Across commercial payers the observed rate range runs roughly from $1.1K (BCBS p25) up to $180K (Anthem max), with mean payer benchmarks spanning from $47K (BCBS) to $89K (Cigna). The widest spread between a payer minimum and maximum appears with Anthem showing values up to $180K versus low-end observations near $390, producing the largest dispersion. See the payer table and accompanying chart below for the full percentile detail by carrier.
The CMS 2023 data represent national Medicare fee-for-service inpatient payments as published in the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($44.4k), average submitted covered charges ($250.9k), average Medicare payment ($35.8k), and total discharges (9.0k).
State Payment Rates
State: Alaska1 / 49
Alaska Benchmarks
Alaska exhibits a broad rate range across payers, from a low of $7.5K to a high of $230K, driven largely by Cigna’s higher reimbursements. Blue Cross Blue Shield and Anthem cluster at a mean of $74K while Cigna’s mean of $140K stands out as a substantial deviation above typical national averages. See the table and chart below for payer-level detail.
Key Insights for Alaska
- Highest payer: Cigna at $140K mean; Lowest payer: BCBS/Anthem at $74K mean.
- Alaska shows a wide state rate range from $7.5K to $230K across payers, with Cigna notably above national mean levels for this DRG.
Clinical Trials
- Acute perioperative intervention trials: randomized or controlled studies testing strategies to reduce intraoperative or immediate postoperative complications in patients undergoing coronary artery bypass grafting (CABG) combined with concurrent cardiac catheterization or open ablation. These studies enroll patients undergoing same-hospitalization CABG with catheter-based diagnostics/interventions or surgical ablation for arrhythmia, and compare approaches such as enhanced myocardial protection protocols, refined anticoagulation timing around catheterization, or blood-sparing techniques. Results inform surgical teams and hospital administrators on interventions that can shorten ICU stays, reduce complications that drive higher resource use, and improve case-mix adjustment for reimbursement.
- Comparative effectiveness research on hybrid procedure timing and sequencing: observational cohorts or pragmatic trials comparing outcomes of combined CABG plus catheterization/ablation performed in a single operative session versus staged procedures during the same admission or separate admissions. These studies focus on older patients or those with multivessel disease and concomitant arrhythmia, evaluating metrics such as composite morbidity, readmission rates, length of stay, and need for repeat revascularization. Findings help clinicians determine which sequencing yields better resource utilization and clinical outcomes, and help payers and hospitals model expected costs and appropriate case grouping for DRG reimbursement.
- Post-discharge outcomes and care-transition studies: prospective registries and quality-improvement trials that follow patients after discharge to assess functional recovery, recurrent ischemia or arrhythmia, rehabilitation adherence, and readmission drivers for patients who had CABG with catheterization or open ablation. These studies often test care-coordination interventions, remote monitoring, or structured cardiac rehabilitation enrollment specifically in this higher-acuity surgical subgroup to reduce 30- and 90-day readmissions. Insights are directly relevant to discharge planning, bundled-payment program performance, and payer strategies to reduce preventable post-discharge costs while improving long-term outcomes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.